Microba Life Sciences (ASX:MAP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Microba Life Sciences (ASX:MAP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Ceasing to be a substantial holder
Letter to Shareholders, Notice of EGM & Proxy Form
Change in substantial holding
Cleansing Notice
Letter to SPP Eligible Shareholders
Microba launches $1 million Share Purchase Plan at $0.05 per share with free options
Disclosure Document - Prospectus
Microba Life Sciences launches $6 million capital raise via SPP and Placement with shareholder approval pending
Application for quotation of securities - MAP
Reinstatement to Quotation
Microba Life Sciences reinstated to ASX quotation after capital raise announcement
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Proposed issue of securities - MAP
Investor presentation - path to cashflow breakeven
Microba announces A$5 million equity raise to fund path to cashflow break-even by 2027 amid strong diagnostics growth and therapeutics partnering
$5M secured to deliver cashflow breakeven and testing growth
Microba raises $5 million to fund growth and achieve cashflow break-even by 2027
Extension of Voluntary Suspension
Suspension from Quotation
Microba Life Sciences requests voluntary suspension pending capital raise and break even update
Trading Halt
Pause in Trading
Microba Life Sciences trading paused pending further announcement
Notification of cessation of securities - MAP
Q3 FY26 Quarterly Investor Presentation & Webinar
Microba reports strong Q3 FY26 growth, on track for regional break-even with new product launches and expanded market penetration
Q3 FY26 Quarterly Activities Report & Appendix 4C
Microba Q3 FY26 core testing revenue doubles; new clinic contracts and UK growth drive momentum
Details of Q3 FY26 Quarterly Report, Appendix 4C & Webinar